• T Conroy, Y Yataghène, P L Etienne, P Michel, H Senellart, J L Raoul, L Mineur, M Rives, X Mirabel, B Lamezec, E Rio, E Le Prisé, D Peiffert, and A Adenis.
• Centre Alexis Vautrin, Department of Medical Oncology, Nancy University, 6 avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy Cedex 54511, France. t.conroy@nancy.fnclcc.fr
• Br. J. Cancer. 2010 Oct 26;103(9):1349-55.

BackgroundConcurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement is still needed. A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil.MethodsPatients with unresectable EC (any T, any N, M0 or M1a), or medically unfit for surgery, were randomly assigned to receive either six cycles (three concomitant and three post-radiotherapy) of FOLFOX4 (arm A) or four cycles (two concomitant and two post-radiotherapy) of cisplatin/fluorouracil (arm B) along with radiotherapy 50 Gy in both arms. Responses were reviewed by independent experts.ResultsA total of 97 patients were randomised (arm A/B, 53/44) and 95 were assessable. The majority had squamous cell carcinoma (82%; arm A/B, 42/38). Chemoradiotherapy was completed in 74 and 66%. The ECRR was 45 and 29% in arms A and B, respectively. Median times to progression were 15.2 and 9.2 months and the median overall survival was 22.7 and 15.1 months in arms A and B, respectively.ConclusionChemoradiotherapy with FOLFOX4, a well-tolerated and convenient combination with promising efficacy, is now being tested in a phase III trial.

24 keywords...

hide…